(Ibuprofen + loratadine) is under clinical development by Laboratorios Silanes and currently in Phase III for Nasal Obstruction. According to GlobalData, Phase III drugs for Nasal Obstruction does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Ibuprofen + loratadine) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ibuprofen + loratadine) overview

Fixed dose combination of ibuprofen and loratadine is under development for the treatment of common cold with sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, and chills. It is administered through oral route as a suspension. Ibuprofen acts by targeting COX-1 and COX-2 and loratadine acts by targeting histamine H1 receptor.

Laboratorios Silanes overview

Laboratorios Silanes is a pharmaceutical company that develops and commercializes innovative medicines. The company’s prescription drugs include captopril, enalapril, carbamazepine and lysine clonixinate. It provides hypertension and metabolic syndrome drugs, antituberculosis drugs, vitamins, antiparasitic drugs, asthma preventives and painkillers. Its therapeutic areas include cardiometabolic, central nervous system, analgesic, antivenoms and respiratory system. The company also offers diagnostics and nutraceutical solutions. Laboratorios Silanes is headquartered in Mexico.

For a complete picture of (Ibuprofen + loratadine)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.